Robert Riesenberg
Psychiatry · Atlanta, GANPI 1417116906
Payments from drug & device makers
Across 3,386 payments — averaging $15,098 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$12M
- AbbVie$10.8M
- Teva Pharmaceuticals USA, Inc.$4.4M
- Sunovion Pharmaceuticals Inc.$4.1M
- Otsuka Pharmaceutical Development & Commercialization, Inc.$3.5M
- Sumitomo Pharma America, Inc.$2.5M
- plus $13.8M from 36 others
Across 7 payments — averaging $836.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$3K
- Eli Lilly$1K
- AbbVie$1K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$48
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$51,122,485 in reported general payments places this provider in the 95th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Atlanta
- Saundra Maass-RobinsonAtlanta$11.1M
- David PurselleAtlanta$7.4M
- Bethany DavisAtlanta$4.4M
- Patricio Riva PosseAtlanta$884K
- Kerry ResslerAtlanta$365K
- Boadie DunlopAtlanta$345K
- Michael BurkeAtlanta$328K
- Bryon EvansAtlanta$211K
- Nurul HoqueAtlanta$145K
- Ray HorwitzAtlanta$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.